Journal of Infectious Diseases & Preventive Medicine
Open Access

The COVID-19 Infection Impact on the Values of Thyroid Hormones

Author info »

Introduction

Thyroid damage has been associated with acute conditions and several viral infections, among which, Hepatitis C Virus (HCV) occupies an important place [1-3]. HCV chronic infection is associated with a multitude of extra hepatic manifestations, either by inflammatory or autoimmune mechanisms [4-7] or even by direct infection of other organs, such as the thyroid. In fact, thyroid involvement is considered as the most frequent endocrine disorder associated with HCV chronic infection; Mechanisms responsible for thyroid damage are thyroid destruction induced by an increased inflammatory response resulting in autoimmune thyroiditis [8] or by direct HCV infection [9].

Important similarities between HCV and COVID 19 have been studied. Both viruses originally thought to have specific targetorgans have proven to be systemic infections. The resemblance between the two viruses originates at a genomic lever, both being single-strained RNA viruses. Furthermore, exacerbation of the immune response, particularly from T helper 2 lymphocytes has been associated with HCV infection and the previous SARS infections, inducing immune-mediated tissue damage, also suspected in COVID-19 [10]. On a molecular level, both HCV and SARS-CoV-2 use ion channels (viroporins) as entry pathways into the cells; these viruses have structurally similar proteins, p7 and E, that bind to viroporins [11]. One of the most important ion channel impairments in both these infections is the damage of chloride channels, essential for several physiologic processes such as neuronal excitation, muscle contraction and transepithelial fluid transportation [12]. In the ongoing SARS-CoV-2 pandemic, hypochloremia has been associated with the diagnosis of COVID-19 and with increased illness severity [13].

Materials and Methods

This study aims to determine the effects of COVID-19 infection on thyroid diseases associated with HCV chronic hepatitis. The study was approved by the local ethics committee. We routinely monitor patients with chronic HCV infection for every 6 months even after obtaining sustained virologic response after direct acting antiviral therapy, in accordance to current guidelines [14]. From April 2020 to October 2020, we performed a prospective observational study on patients with cured HCV infection and documented thyroid disease that became infected with SARS CoV-2.

Inclusion criteria for the current study were:

• History of HCV chronic hepatitis, with undetectable HCVRNA at three months, after direct- acting antiviral therapy (either ombitasvir/ paritaprevir/ritonavir and dasabuvir or ledipasvir/ sofosbuvir);

• Documented thyroid disease (autoimmune thyroiditis, hyperthyroidism or hypothyroidism) with antibody and hormonal determination within 6 months before COVID-19 infection;

• Documented COVID-19 infection cured within a month before the first visit.

The exclusion criteria were:

• History of thyroid cancer associated to HCV chronic infection;

• Hepatitis B virus or HIV co-infection;

• Changes in thyroid substitution therapy or anti-thyroid drugs within 6 months of the first visit;

• Decompensated cirrhosis, solid or hematological neoplasia.

Demographic and medical data were retrieved from electronic source documents. Evaluation at one and three months after COVID-19 infection included serum determination of antithyroid antibodies, Anti-Thyroglobulin (anti-TG) and Anti- Thyroid Peroxidase (ATPO), Thyroid-Stimulating Hormone (TSH), free Thyroxin (fT4), free Triiodothyronine (fT3), and evaluation of thyroid medication, with dose adjustment if required. TSH, fT3, fT4 and anti-TG antibodies were determined using electro chemiluminescence assays (normal values between 0.27 and 4.2 μUI/mL for TSH, between 2.2 and 4.4 pg/ml for fT3, between 12 and 22 pmol/l for fT4 and less than 115 IU/ml for anti-TG) while ATPO were determined using chemiluminescence with micro particles (normal values less than 34 IU/ml).

Data was evaluated using statistical software SPSS. Numerical values were expressed as mean ± standard deviation. ANOVA test was performed in order to compare values at the three visits of evaluation, considering statistical significance at a p-value less than 0.05.

Within our study group, patients with evidence of thyroid hormone impairment were defined as either having hypothyroidism or hyperthyroidism (regardless of the underlying mechanism and regardless of the presence/absence of autoimmune antibodies), while all patients referred to as having “autoimmune thyroiditis” had euthyroidism. We only use the term autoimmune thyroiditis, if the patient had normal thyroid hormones and could not be classified in any of the two subgroups (hypothyroidism or hyperthyroidism).

Results and Discussion

A total of 42 patients were included in the study, with a mean age of 52.67 years, female patients representing 64.28%. Baseline characteristics of the study group are presented in Table 1. Out of the 42 patients, 7 patients were receiving medication for thyroid disease: 5 patients with hypothyroidism were receiving levothyroxine (mean dose of 55.4 mcg daily) and 2 patients with hyperthyroidism were receiving methimazole (mean dose of 7.5 mg daily).

Table 1: Baseline characteristics of the study group.

36 patients had mild COVID-19 infection, while 6 patients had a moderate form of infection. The most frequent symptoms were: myalgia (34/42 patients), fatigue (31/42 patients), fever (25/42 patients), headache (21/42 patients) and digestive symptoms (23/42 patients).

At one month follow-up, we found an increase in anti-thyroid antibodies, in patients with autoimmune thyroiditis as well as patients with baseline normal values of antibodies. In patients with autoimmune thyroiditis, mean values of ATPO were 1187.7 ± 285 IU/ml (versus 982.1 ± 426.6 IU/ml at baseline, p=0.02) and mean values of anti-TG were 563.2 ± 193.1 IU/ml (versus 324.2 ± 132.21 IU/ml at baseline, p=0.01). In patients without autoimmune thyroiditis, ATPO levels increased to 123.7 ± 32.8 IU/ml (versus 18.4 ± 7.2 IU/ml at baseline, p<0.01) and anti-TG values increased to 134.8 ± 42.2 IU/ml (versus 65.9 ± 21.7 IU/ml at baseline, p=0.03). Furthermore, we found a significant decrease in TSH, fT3 and fT4 levels in patients with euthyroidism. The results are presented in Table 2. Treatment was discontinued in 2 patients receiving levothyroxine and one patient receiving methimazole.

Table 2: Evolution of TSH, FT3 and FT4 in patients with euthyroidism and dysthyroidism after COVID-19 infection.

At 3 months follow-up, we noted a significant decrease in ATPO levels (84.13 ± 25.12 IU/ml versus 123.7 ± 32.8 IU/ml, p=0.02, in patients without autoimmune thyroiditis and 843 ± 205 IU/ml versus 1187.7 ± 285 IU/ml, p=0.01, in patients with autoimmune thyroiditis). Anti-TG levels were significantly lower in patients with autoimmune thyroiditis (408 ± 113.2 IU/ml versus 563.2 ± 193.1 IU/ml, p=0.01) and in patients without autoimmune thyroiditis (86.21 ± 18.48 IU/ml versus 134.8 ± 42.2 IU/ml, p=0.03). We also noted an increase in TSH, FT3 and FT3 levels, without statistical significance, except FT4 levels in patients with euthyroidism. Patients receiving levothyroxine or methimazole did not require dose adjustment or drug discontinuation. Also, the patients that discontinued medication (with either levothyroxine or methimazole) did not require any treatment restoration within three months of followup.

The present study shows that COVID-19 infection influences the thyroid function and the presence and levels of anti-thyroid antibodies in patients with pre-existent conditions associated with HCV chronic infection. It is a well-known fact that there is a thyroid response associated with systemic inflammation; a “low triiodothyronine” syndrome has been described in association with sepsis, potentially accompanied by low levels of T4 [15]. Moreover, septic shock may induce hypophyseal hypo perfusion, causing central hypothyroidism [16]. It has also been shown that decreased baseline thyroid function is associated with a poor prognosis in patients with sepsis or septic shock, independent of other prognostic factors [17]. Sepsis induced thyroid dysfunction appears to be a transient condition and may represent an adaptive mechanism, in order to protect the thyroid from cellular death caused by systemic inflammatory response syndrome. Furthermore, there are several pro-inflammatory cytokines (IL1β, IL6 and TNF-α) that have inhibitory effects on the thyroid function [18]. These mechanisms partially explain the results of our study, particularly the decrease in TSH, fT3 and fT4 levels shortly after COVID-19 infection.

Recent articles have tackled the varieties of thyroid disease associated with COVID-19 infection, regardless of a preexistent thyroid dysfunction or HCV infection. In a case series, it has been suggested that COVID-19 may induce sub-acute thyroiditis, developing as late as 36 days after COVID-19 typical symptoms [19]. The four patients report presented with thyrotoxicosis and received low-dose steroid therapy. Incidence of thyroiditis in intensive-care unit patients has also been evaluated in a prospective study comparing COVID-19 infected to non-infected patients [20]. This study also presents a high incidence of thyrotoxicosis in the COVID-19 subgroup without underlying thyroid disease. Another large single center retrospective study found a high incidence of thyroid dysfunction in 278 patients admitted to non-intensive care units for COVID-19 infection: Thyrotoxicosis in 20.2% and hypothyroidism in 5.2% [21]. On the other hand, a retrospective study on 50 patients with COVID-19 infection without previous thyroid disease found low levels of TSH and total triiodothyronine, which normalized after the infection resolution [22]. Furthermore, a large multicenter trial including 621 patients reports lower values of TSH and FT4 in COVID-19 infected patients than in non-infected patients. Interestingly, none of the patients in this study presented overt thyrotoxicosis. [23]. A recent systematic review found a prevalence of thyroid dysfunction ranging from 13%-64% in total number of 1237 patients [24].

Inconclusive data also emerge when studying the impact of COVID-19 on patients with a history of thyroid illness. A report of two cases presents the recurrence of Graves’ disease during infection, both after more than 2 years of stable thyroid function without medication [25]. An article regarding the relationship between thyroid cancer and COVID-19 shows an increased prevalence of the infection in this subgroup of patients [26]. The presence of thyroid cancer appears not to be an additional risk factor for mortality in COVID-19 [27].

To our knowledge, none of the articles published analyze the impact of COVID-19 on patients with HCV- induced thyroid disease, although this is a frequently encountered condition. A systematic review published in 2016 showed an increased prevalence of high anti-TG and ATPO antibodies and a 3 fold risk of hypothyroidism in patients with HCV chronic infection [28]. Modern interferon free therapies in HCV infection, associated with high cure rates and few adverse reactions, are expected to reduce the rate and severity of HCV extra hepatic manifestations [29,30]. It appears that HCV- associated thyroid disorders may persist after all oral antiviral therapy but less frequent and severe than after the classical interferon-based regimens [31-35].

Our study reveals that COVID-19 infection has a significant impact on the values of thyroid hormones and antibodies and may lead to medication adjustments in patients with known thyroid illness. However, the study has several limitations:

• Absence of patients with severe COVID-19 infection,

• Insufficient data regarding corticoid therapy received during infection and a small number of patients,

• Not permitting sufficient correlations to the stage of liver disease.

Our findings regarding COVID-19 consequences among HCVinfected patients with preexistent thyroid dysfunction are comparable with those described by other recent studies (that included patients without known HCV-induced thyroidal dysfunction) [19-24].

Conclusion

In conclusion, we highly recommend monitoring thyroid hormones and antibodies during COVID-19 infection in all patients, as uncovering the mechanisms responsible for thyroid disease may contribute to the better evaluation and management of these patients. Nevertheless, even during world medical crises such as the one we are enduring, it is important to keep in mind that patients require medical attention for a multitude of reasons and diseases, and medical care and monitoring should not be discontinued.

References

1. Temgoua MN, Endomba FT, Nkeck JR, Kenfack GU, Tochie JN, Essouma M. Coronavirus Disease 2019 (COVID-19) as a multi-systemic disease and its impact in low- and middle-income countries (LMICs). SN Compr Clin Med. 2020;1(1): 1-11.
2. Scappaticcio L, Pitoia F, Esposito K, Piccardo A, Trimboli P. Impact of COVID-19 on the thyroid gland: An update. Rev Endocr Metab Disord. 2020;1(1): 1-13.
3. Cacoub P, Comarmond C, Domont F, Savey L, Desbois AC, Saadoun D. Extrahepatic manifestations of chronic hepatitis C virus infection. Ther Adv Infect Dis. 2016;3(1): 3-14.
4. Obrișcă B, Jurubiță R, Sorohan B, Iliescu L, Baston C, Bobeică R, et al. Clinical outcome of HCV-associated cryoglobulinemic glomerulonephritis following treatment with direct acting antiviral agents: A case-based review. Clin Rheumatol. 2019;38(12): 3677-3687.
5. Iliescu L, Herlea V, Toma L, Orban C. Association between chronic HCV hepatitis, membranoproliferative glomerulopathy and cutaneous sarcoidosis. J Gastrointestin Liver Dis. 2015;24(1): 1-8
6. Iliescu L, Mercan-Stanciu A, Ioanitescu ES, Toma L. Hepatitis c-associated b-cell non-hodgkin lymphoma: a pictorial review. Ultrasound Q. 2018;34(3): 156-166.
7. Iliescu L, Mercan-Stanciu A, Toma L, Ioanitescu ES. A severe case of hyperglycemia in a kidney transplant recipient undergoing interferon-free therapy for chronic hepatitis C. Acta Endocrinol. 2018;14(4): 533-538.
8. Ferri C, Colaci M, Fallahi P, Ferrari SM, Antonelli A, Giuggioli D. Thyroid involvement in hepatitis c virus-infected patients with/without mixed cryoglobulinemia. Front Endocrinol. 2017; 8(1): 159.
9. Pastore F, Martocchia A, Stefanelli M, Prunas P, Giordano S, Toussan L, et al. Hepatitis C virus infection and thyroid autoimmune disorders: A model of interactions between the host and the environment. World J Hepatol. 2016; 8(2): 83-91.
10. Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LFP. The trinity of COVID-19: Immunity, inflammation and intervention. Nat Rev Immunol. 2020;20(6): 363-374.
11. Surya W, Li Y, Torres J. Pentameric viral ion channels: from structure to function. J Recept Ligand Channel Res. 2015;8: 9-18.
12. Liu B, Billington CK, Henry AP, Bhaker SK, Kheirallah AK, Swan C, et al. Chloride intracellular channel 1 (CLIC1) contributes to modulation of cyclic AMP-activated whole-cell chloride currents in human bronchial epithelial cells. Physiol Rep. 2018;6(2): e13508.
13. Alothaid H, Aldughaim MSK, ElBakkouri K, AlMashhadi S, Al-Qahtani AA. Similarities between the effect of SARS-CoV-2 and HCV on the cellular level, and the possible role of ion channels in COVID-19 progression: A review of potential targets for diagnosis and treatment. Channels (Austin). 2020; 14(1): 403-412.
14. European Association for the Study of the Liver. Clinical Practice Guidelines Panel: Chair; EASL Governing Board Representative. EASL recommendations on treatment of hepatitis C: Final update of the series. J Hepatol. 2020;73: 1170-1218
15. Luo B, Yu Z, Li Y. Thyroid hormone disorders and sepsis. Biomed Mater Eng. 2017;28(s1): S237-S241.
16. Benea SN, Lazar M, Hristea A, Hrisca RM, Niculae CM, Moroti RV. Central hypothyroidism in severe sepsis. Acta Endocrinol. 2019;15(3): 372-377.
17. Angelousi AG, Karageorgopoulos DE, Kapaskelis AM, Falagas ME. Association between thyroid function tests at baseline and the outcome of patients with sepsis or septic shock: a systematic review. Eur J Endocrinol. 2011;164(2): 147-155.
18. McIver B, Gorman CA. Euthyroid sick syndrome: An overview. Thyroid. 1997;7(1): 125-132.
19. Brancatella A, Ricci D, Cappellani D, Viola N, Sgrò D, Santini F, et al. Is subacute thyroiditis an underestimated manifestation of sars-cov-2 infection? insights from a case series. J Clin Endocrinol Metab. 2020;105(10): e3742-3746.
20. Muller I, Cannavaro D, Dazzi D, Covelli D, Mantovani G, Muscatello A, et al. SARS-CoV-2-related atypical thyroiditis. Lancet Diabetes Endocrinol. 2020;8(9): 739-741.
21. Lania A, Sandri MT, Cellini M, Mirani M, Lavezzi E, Mazziotti G. Thyrotoxicosis in patients with COVID-19: The THYRCOV study. Eur J Endocrinol. 2020;183(4): 381-387.
22. Chen M, Zhou W, Xu W. Thyroid function analysis in 50 patients with covid-19: a retrospective study. Thyroid. 2021;31(1): 8-11.
23. Khoo B, Tan T, Clarke SA, Mills EG, Patel B, Modi M, et al. Thyroid function before, during and after covid-19. J Clin Endocrinol Metab. 2021;106(2): e803-e811.
24. Giovanella L, Ruggeri RM, Ovčariček PP, Campenni A, Treglia G, Deandreis D. Prevalence of thyroid dysfunction in patients with COVID-19: A systematic review. Clin Transl Imaging. 2021;(11): 1-8.
25. Jiménez-Blanco S, Pla-Peris B, Marazuela M. COVID-19: A cause of recurrent Graves' hyperthyroidism? J Endocrinol Invest. 2021; 44(2): 387-388.
26. Prete A, Falcone M, Bottici V, Giani C, Tiseo G, Agate L, et al. Thyroid cancer and COVID-19: Experience at one single thyroid disease referral center. Endocrine. 2021; 27(1): 1–8.
27. Kathuria-Prakash N, Mosaferi T, Xie M, Antrim L, Angell TE, In GK, et al. COVID-19 outcomes of patients with differentiated thyroid cancer: A multicenter Los Angeles cohort study. Endocr Pract. 2021;27(2): 90-94
28. Shen Y, Wang XL, Xie JP, Shao JG, Lu YH, Zhang S, et al. Thyroid disturbance in patients with chronic hepatitis c infection: A systematic review and meta-analysis. J Gastrointestin Liver Dis. 2016;25(2): 227-234.
29. Iliescu EL, Mercan-Stanciu A, Toma L. Safety and efficacy of direct-acting antivirals for chronic hepatitis C in patients with chronic kidney disease. BMC Nephrol. 2020;21(1): 1-21.
30. Iliescu L, Mercan-Stanciu A, Toma L, Dodot M, Isac T, Grumeza M. All Oral Antiviral Treatment with Paritaprevir/Ombitasvir/Ritonavir and Dasabuvir in Chronic HCV Infection-Real Life Experience. Proc 35th Balk Med Week. 2018;1(1): 138-143.
31. Zignego AL, Ramos-Casals M, Ferri C, Saadoun D, Arcaini L, Roccatello D, et al. International therapeutic guidelines for patients with HCV-related extrahepatic disorders: A multidisciplinary expert statement. Autoimmun Rev. 2017;16(5): 523-541.
32. Wahid B, Waqar M, Rasool N, Wasim M, Khalid I, Idrees M. Prevalence of thyroid stimulating hormone dysfunction among sofosbuvir-treated HCV-infected patients: A real-world clinical experience. J Med Virol. 2019;91(3): 514-517.
33. Zgura A, Gales L, Bratila E, Mehedintu C, Haineala B, Barac RI, et al. Variation of the T Lymphocytes according to treatment in breast cancer. Rev Chim. 2019;70(5): 1649-1654.
34. Bacinschi XE, Zgura A, Safta I, Anghel R. Biomolecular factors represented by bcl-2, p53, and tumor-infiltrating lymphocytes predict response for adjuvant anthracycline chemotherapy in patients with early triple-negative breast cancer. Cancer Manag Res. 2020;12(1): 11965.
35. Zgura A, Gales L, Haineala B, Bratila E, Mehedintu C, Andreescu CV, et al. Correlations between known prognostic markers and tumor- infiltrating lymphocytes in breast cancer. Rev Chim. 2019;70(7): 2362-2366.